Prospera^™

For kidney transplant assessment

Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.

Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Surveilling your new kidney with a more precise blood draw

More informed, better protection

You and your provider understand the importance of preserving the function of a newly transplanted kidney. Achieving this goal could mean avoiding both dialysis and returning to the transplant list.

Early, informed treatment of underlying disease and patient adherence to medications are essential to preserving kidney function.

Surveilling your kidney with a single blood draw

How does it work?

From a single blood draw, Prospera measures the amount of donor DNA from your transplanted kidney in your blood. This helps your care team assess all types of rejection more precisely than available standard assessment tools.^1-4

Download Brochure

What do the Prospera results mean to me?

The Prospera result represents the percent of cell-free DNA in your blood that originates from the donated kidney to determine whether or not you may be experiencing active rejection. It may also indicate other types of kidney injury you are experiencing.

Like your other regular monitoring tests, Prospera is recommended for periodic use over time as directed by your doctor.

A way to track your cell-free DNA over time

Establishing a baseline tells you and your care team the “normal state” of your new kidney. You can measure new results against this baseline.
Following your levels in the future reveals your new kidney’s health

If a Prospera result is above 1%

This may mean that active rejection is occurring². Terms used to describe the various types of active rejection include:

Antibody-mediated rejection
T cell-mediated rejection
Mixed rejection

To confirm a rejection or the type of rejection, you should consult your doctor.

If a Prospera result is in the normal range

This may mean that your kidney is stable².

ProsperaLink Program: Your Support Team

We offer complete support through our Prospera Link Program:

Always by your side: Natera’s care team will guide you through the process of using Prospera and check-in with you at every milestone
Flexible for your convenience: Our team coordinates blood draws around your schedule — at a certified laboratory near you or by a blood draw specialist who can come to you
Transparent & accessible: Our proactive billing outreach and flexible payment plans, including assistance for hardship, help ensure no significant financial hardship in accessing Prospera. Natera welcomes all insurances. Prospera is covered by Medical for assessing potential kidney transplant rejection.

Sign up to find out if you’re eligible for Prospera

References

¹Altug Y et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation. 2019

²Sigdel TK et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.

³Grskovic M et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn.2016;18(6):890-902.

⁴Bloom RD et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

Prospera™